

# Shivani Patel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/88444438/publications.pdf>

Version: 2024-02-01

14  
papers

2,970  
citations

840776

11  
h-index

996975

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

6505  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	27.8	995
2	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	27.8	765
3	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	7.4	307
4	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	7.4	260
5	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 951-953.	27.0	192
6	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. <i>Cell</i> , 2020, 183, 1354-1366.e13.	28.9	184
7	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	27.8	71
8	Low-dose Ad26.COVS protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	28.9	49
9	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	27.8	40
10	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.	10.3	27
11	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	12.4	15
12	Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. <i>Nature</i> , 2022, 601, 612-616.	27.8	14
13	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoVS vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	5.6	14
14	Passive transfer of Ad26.COVS-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. <i>Npj Vaccines</i> , 2022, 7, 2.	6.0	2